LONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced publication of a ‘Comment’ in Nature Cancer that outlines the vast potential of neoantigen immunogenicity prediction, discusses current limitations in the field that limit performance, and proposes a path forward.

伦敦，2023年12月18日（环球通讯社）--阿喀琉斯治疗公司（纳斯达克：ACHL），一家临床阶段的生物制药公司，开发针对克隆新抗原治疗实体瘤的人工智能精确T细胞疗法，今天宣布在《自然癌症》杂志上发表一篇“评论”，概述了新抗原免疫原性预测的巨大潜力，讨论了当前限制性能的领域限制，并提出了前进的道路。

The article, entitled Breaking the performance ceiling for neoantigen immunogenicity prediction, makes the case that the efficient and accurate selection of immunogenic neoantigens is a critical determinant in neoantigen-based personalized tumor therapies. Selecting which neoantigens to use in drug development based on their immunogenicity is crucial for efficacy of personalized treatments as only a few neoantigens will be clinically relevant.

这篇题为《打破新抗原免疫原性预测的性能上限》的文章提出，有效而准确地选择免疫原性新抗原是基于新抗原的个性化肿瘤治疗的关键决定因素。根据其免疫原性选择用于药物开发的新抗原对于个性化治疗的功效至关重要，因为只有少数新抗原具有临床相关性。

The authors of the ‘Comment’ are all researchers affiliated with the DECOD-Ag consortium of which Achilles Therapeutics is a member. They note recent improvements in computational immunogenicity-prediction models and suggest that the performance of currently available artificial intelligence (AI) methods for immunogenicity ranking will be surpassed by robust prediction algorithms built from larger datasets with lower bias.

“评论”的作者都是DECOD Ag财团的研究人员，Achilles Therapeutics是该财团的成员。他们注意到计算免疫原性预测模型的最新改进，并建议目前可用的人工智能（AI）免疫原性排名方法的性能将被从较大数据集构建的具有较低偏差的稳健预测算法所超越。

Achilles has built a world-leading, AI-powered PELEUS™ bioinformatics platform to identify clonal neoantigens from each patient’s unique tumor profile. The proprietary PELEUS™ platform was developed and validated with sequence data from the landmark TRACERx study led by Achilles co-founder Professor Charles Swanton of the Crick Institute.

阿基里斯（Achilles）建造了一个世界领先的人工智能动力PELEUS™生物信息学平台，用于从每位患者独特的肿瘤特征中鉴定克隆新抗原。专有PELEUS™该平台是由克里克研究所的阿基里斯联合创始人查尔斯·斯旺顿教授领导的具有里程碑意义的TRACERx研究的序列数据开发和验证的。

Achilles has exclusive commercial rights to the TRACERx study, which has generated one of the largest data sets ever collect.

阿喀琉斯拥有TRACERx研究的专有商业权利，该研究产生了有史以来收集的最大数据集之一。